다우존스 지수

같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.

등록

홈
인베스팅
주식
미국
NYSE
Oaktree Acquisition Corp II (OACB)
Oaktree Acquisition Corp II (OACB) 뉴스

OACB

Oaktree Acquisition Corp... (OACB)

Oaktree Acquisition Corp II

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NYSE:OACB

1 2 3 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2022/06/16	00:36	Edgar (US Regulatory)	Notification Filed by a National Securities Exchange to Report the Removal From Listing and Registration of Matured , Redeemed or Retired Securities (25)	NYSE:OACB	Oaktree Acquisition Corp II
2022/06/09	20:10	Edgar (US Regulatory)	Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)	NYSE:OACB	Oaktree Acquisition Corp II
2022/06/09	10:16	Business Wire	Alvotech und Oaktree Acquisition Corp. II melden Zustimmung der Aktionäre zum Unternehmenszusammenschluss	NYSE:OACB	Oaktree Acquisition Corp II
2022/06/08	18:54	Business Wire	Alvotech et Oaktree Acquisition Corp. II annoncent l'approbation des actionnaires pour le regroupement d'entreprises	NYSE:OACB	Oaktree Acquisition Corp II
2022/06/08	05:00	Business Wire	Alvotech and Oaktree Acquisition Corp. II Announce Shareholder Approval of Business Combination	NYSE:OACB	Oaktree Acquisition Corp II
2022/06/04	06:29	Edgar (US Regulatory)	Current Report Filing (8-k)	NYSE:OACB	Oaktree Acquisition Corp II
2022/06/04	06:17	Business Wire	Oaktree Acquisition Corp. II Announces Delisting of its Securities Effective and Conditional Upon Consummation of its Pending Business Combination with Alvotech	NYSE:OACB	Oaktree Acquisition Corp II
2022/06/01	06:19	Edgar (US Regulatory)	Current Report Filing (8-k)	NYSE:OACB	Oaktree Acquisition Corp II
2022/05/24	20:24	Edgar (US Regulatory)	Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)	NYSE:OACB	Oaktree Acquisition Corp II
2022/05/24	20:00	Business Wire	Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT04 and Reference Product Stelara®	NYSE:OACB	Oaktree Acquisition Corp II
2022/05/17	22:00	Edgar (US Regulatory)	Current Report Filing (8-k)	NYSE:OACB	Oaktree Acquisition Corp II
2022/05/17	04:08	Edgar (US Regulatory)	Quarterly Report (10-q)	NYSE:OACB	Oaktree Acquisition Corp II
2022/05/16	21:07	Edgar (US Regulatory)	Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)	NYSE:OACB	Oaktree Acquisition Corp II
2022/05/16	21:00	Business Wire	Alvotech Announces Positive Results from a Pharmacokinetic Similarity Study for AVT04, a Proposed Biosimilar to Stelara®	NYSE:OACB	Oaktree Acquisition Corp II
2022/05/11	21:00	Business Wire	Alvotech, Global Biotech Company, and Oaktree Acquisition Corp. II Announce June 7, 2022 Extraordinary General Meeting to Approve Business Combination	NYSE:OACB	Oaktree Acquisition Corp II
2022/05/11	07:34	Edgar (US Regulatory)	Proxy Statement - Merger or Acquisition (definitive) (defm14a)	NYSE:OACB	Oaktree Acquisition Corp II
2022/04/23	05:31	Edgar (US Regulatory)	Current Report Filing (8-k)	NYSE:OACB	Oaktree Acquisition Corp II
2022/04/21	06:00	Business Wire	Alvotech améliore son accès aux capitaux et optimise son processus d’entrée en bourse, prévue sur le NASDAQ	NYSE:OACB	Oaktree Acquisition Corp II
2022/04/21	01:45	Business Wire	Alvotech verbessert Zugang zu Kapital und ebnet Weg für erwartete NASDAQ-Notierung	NYSE:OACB	Oaktree Acquisition Corp II
2022/04/20	21:15	Business Wire	Alvotech migliora l'accesso al capitale e semplifica il percorso verso la prevista quotazione in Borsa al NASDAQ	NYSE:OACB	Oaktree Acquisition Corp II
2022/04/20	07:00	Business Wire	Alvotech Improves Access to Capital and Streamlines Path to Expected Public Listing on NASDAQ Stock Exchange	NYSE:OACB	Oaktree Acquisition Corp II
2022/04/20	06:26	Edgar (US Regulatory)	Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)	NYSE:OACB	Oaktree Acquisition Corp II
2022/04/19	06:12	Edgar (US Regulatory)	Current Report Filing (8-k)	NYSE:OACB	Oaktree Acquisition Corp II
2022/04/08	23:01	Business Wire	アルヴォテックとSTADA、アッヴィとの欧州特許紛争を解決してHumira®のクエン酸フリー高濃度バイオシミラーHUKYNDRA®（AVT02）発売への道を開く	NYSE:OACB	Oaktree Acquisition Corp II
2022/04/07	10:15	Business Wire	Alvotech et STADA ouvrent la voie au lancement de HUKYNDRA® (AVT02), un biosimilaire de l'Humira® haute concentration sans citrate, en réglant le litige de brevet européen qui les opposait à AbbVie	NYSE:OACB	Oaktree Acquisition Corp II
2022/04/07	07:21	Business Wire	Alvotech und STADA ebnen durch Beilegung des europäischen Patentstreits mit AbbVie den Weg für die Markteinführung von HUKYNDRA®(AVT02), einem zitratfreien, hochkonzentrierten Biosimilar zu Humira®	NYSE:OACB	Oaktree Acquisition Corp II
2022/04/06	20:51	Edgar (US Regulatory)	Current Report Filing (8-k)	NYSE:OACB	Oaktree Acquisition Corp II
2022/04/06	20:00	Business Wire	Alvotech and STADA Pave Way to Launching HUKYNDRA®(AVT02), a Citrate-free, High-concentration Biosimilar to Humira® by Resolving European Patent Dispute With AbbVie	NYSE:OACB	Oaktree Acquisition Corp II
2022/03/24	05:20	Edgar (US Regulatory)	Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)	NYSE:OACB	Oaktree Acquisition Corp II
2022/03/14	20:10	Business Wire	アルヴォテックがアッヴィとの米国特許・企業秘密紛争を解決し、Humira®向けにアルヴォテックが提案中の高濃度バイオシミラー（AVT02）の米国での権利を確保	NYSE:OACB	Oaktree Acquisition Corp II

검색 관련기사 보기:NYSE:OACB

1 2 3 다음 >>

Verizon Communications

Bank of America

Deutsche Telekom (QX)

US Dollar vs Euro

JP Morgan Chase

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관